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Drug discovery is an inherently multi-objective process
since drugs need to satisfy not only activity requirements
but also a range of other properties such as selectivity and
toxicity. However, drug discovery process practices,
including both experimental and computational meth-
ods, commonly ignore this fact and focus on a single
pharmaceutical objective at a time. De novo design, the
branch of chemoinformatics addressing the in silico design
of ligands from scratch, follows a similar approach typi-
cally focusing on a single objective, such as an interaction
score to a target receptor or similarity to a known drug [1].
Recently, methods have appeared in the literature that
attempt to design molecules satisfying multiple prede-
fined objectives [2]. Motivated from the initial success of
these algorithms [3] – as well as their widespread use in
other scientific fields – we have preciously introduced
MEGA, a Multi-objective Evolutionary Graph Algorithm
with the aim of performing de novo design taking into
account numerous pharmaceutically relevant objectives.
Unlike most other evolutionary-based de novo algo-
rithms, MEGA uses graph data structures for chromosome
representation and directly manipulates the graphs to per-
form a global search for promising solutions. The initial
version of the algorithm includes problem-domain spe-
cific knowledge in the form of weighted molecular frag-
ments used during chemical structure evolution.
Capitalizing on lessons learned we have designed an
extension blending additional problem knowledge and
local search capabilities to achieve faster convergence.
This type of algorithm, commonly referred to as Memetic
in the optimization community, has been shown to be
orders of magnitude faster than traditional evolutionary
algorithms [4] especially in problems searching large,
complex and multimodal solution surfaces.
In our presentation we initially outline the key elements
of the implementation of our algorithm. Following, we
present results from the application of the memetic ver-
sion of MEGA to design molecules that satisfy multiple
objectives. Several test cases have been examined, includ-
ing selectivity between targets and compromising similar-
ity to a drug and drug-likeness. The results show that the
inclusion of domain specific knowledge has a positive
impact and should in principle be exploited since it facil-
itates the practical use of methods incorporating multi-
objective de novo design.
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